SEC Tracker
Get the app

Gilead Sciences GILD

Gilead Sciences Q2 FY26: revenue $7.8B, up 10%; diluted EPS −$8.45

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Gilead Sciences reported for Q2 FY26, the quarter ended Jun 30, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$7.8B+10% from $7.1B in Q2 FY2510-Q income statement, on EDGAR
  2. Net income−$10.5B−636% from $2.0B in Q2 FY2510-Q income statement, on EDGAR
  3. Diluted EPS−$8.45−642% from $1.56 in Q2 FY2510-Q income statement, on EDGAR
  4. Cash and cash equivalents$3.2B−38% from $5.1B in Q2 FY25Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations$3.6B+332% from $827.0M in Q2 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Gilead Sciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float over $2B, nearest public float first, as each company reports it on its annual report cover.

  1. Amgen AMGN public float $150.1B, Jun 30, 2025
  2. Biogen BIIB public float $18.4B, Jun 30, 2025
  3. Moderna MRNA public float $9.9B, Jun 30, 2025
  4. Neurocrine Biosciences NBIX public float $9.5B, Jun 30, 2025
  5. Exelixis EXEL public float $9.4B, Jul 4, 2025